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IFNs comprise three genetically determined classes (a, ,8, and 'y) and at least
eight subtypes of IFN-a (1) . IFN-a and -ß are produced in response to viral
infections and compete for presumably common receptors (2, 3) . IFN-y is a
product of activated lymphocytes that differs structurally and functionally from
IFN-a/ß (4) and binds to distinct receptors (2, 5, 6) . The binding properties of
IFN receptors have been investigated on various cells ; the structural elements of
these receptors, however, have not been characterized as yet (for reviews see
references 7, 8) . Crosslinking experiments with 1251-labeled rIFN-y revealed
ligand/receptor complexes within an M,. range between 70,000 and 140,000 (9-
12) . We now report the production of mAbs against IFN-y receptors of human
Raji cells and the use of these antibodies together with immobilized recombinant
human IFN-y (rhuIFN-y)' for sequential affinity purification of the receptor
protein(s).
Materials and Methods
Interferon.
￿
rhuIFN-y with a specific activity of 2 X 10' U/mg of protein was kindly
provided by Dr . C . Weissmann, Institute of Molecular Biology I, University of Zurich .
Labeling with 1251 was carried out as follows : 25 ag rhuIFN-y were reacted for 1 min at
room temperature with 2 mCi carrier-free Na
1251 (200 mCi/ml ; Eidgen6ssisches Institut
fiir Reaktorforschung, Wilrenlingen, Switzerland) in 100 ul PBS, pH 7 .2, after addition
of 10 gl 0 .05% wt/vol chloramineT . The reaction was stopped by addition of 10 ttl 0.05%
wt/vol sodium pyrosulfite and the labeled protein was separated from free iodine by gel
filtration on a prepacked Sephadex G-25 PD-10 column (Pharmacia Fine Chemicals,
Uppsala, Sweden) equilibrated with PBS containing 10%FCS (KC Biological, Inc ., Lenexa,
KS) . The protein fraction was diluted 10-fold in RPMI 1640 medium (Gibco Laboratories,
Grand Island, NY) containing 10 mM Hepes buffer (Gibco Laboratories) and 10% FCS .
The specific radioactivity of 1'251-labeled huIFN gamma ranged from 30 to 50 uCi/wg of
rhuIFN-y as determined by precipitation of proteins with 10% TCA . This range of
specific radioactivity, which corresponds to a substitution ratio of about 0.3, was found to
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' Abbreviation used in this paper:
￿
rhuIFN-7, recombinant human interferon Y .
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give the best ratio between specific and nonspecific high-affinity binding to cell surface
receptors under saturating conditions . No loss of antiviral activity could be measured
upon labeling . The sensitivity ofthe IFN assay does not allow detection ofa loss of activity
below 30% ; it cannot be excluded, therefore, that labeled rhuIFN- ,y that shows specific
binding to high-affinity cell surface receptors is in part biologically inactive . The binding
properties relevant to the experiments reported herein remained unchanged upon storage
at -70 °C for several months.
Interferon Neutralization Assay .
￿
rhuIFN-y was assayed on human WISH cells (Gibco
Laboratories) challenged with vesicular stomatitis virus . WISH cells were grown as
monolayer cultures in Dulbecco's modified MEM (Gibco Laboratories) supplemented with
10% FCS . 1 U/ml ofhuIFN-y is defined as the concentration that results in50% protection
from the cytopathic effect . Neutralization of this antiviral activity by mAbs was titrated
by serial dilutions in cell culture medium of ascitic fluid against 4-8 U/ml of rhuIFN-y .
Cells.
￿
The continuous human Burkitt lymphoma lines Raji, P-3HR,, Daudi, Namalwa,
and mouse L1210 cells were grown in nonagitated cultures in RPMI 1640 medium
containing 10% FCS . Binding experiments and cell fractionation were carried out with
exponentially growing cells expanded to a density of at most 106 cells/ml . Raji cells that
were used for extraction ofmembrane proteins were grown in agitated suspension cultures
of 5 liters in the same medium .
Cell Lysates.
￿
5 liters ofRaji cell cultures corresponding to 5 X 109 cells were centrifuged
at 400 g for 15 min at 4°C and the pellet was resuspended in 20 ml 10mM Tris/Cl (pH
7.2)/100 U/ml aprotinin (Trasylol ; Bayer, Leverkusen, Federal Republic of Germany).
After 10 min incubation on ice, cells were subjected to Dounce homogenization and an
equal volume of 10 mM Tris/Cl (pH 7 .2)/0 .5 M sucrose/100mM KCl/10 mM MgC12/2
mM CaC12/100 U/ml aprotinin was added . This suspension was centrifuged at 2,000 g
for 15 min at 4°C and the microsomal fraction contained in the supernatant was
subsequently pelleted at 100,000 g for 90 min at 4°C. This membrane-enriched fraction
was resuspended in 20 ml 10 mM Tris/Cl (pH 7.2)/150 mM NaCl (TBS)/0.1 M su-
crose/100 U/ml aprotinin and kept frozen at -20°C .
Immunization and Cell Fusion .
￿
Membrane-enriched fractions of ~5 X 10'° human Raji
cells were affinity purified on rhuIFN-y coupled to Affigel-10 as described below . One 4-
wk-old female BALB/c mouse was immunized with the pooled eluates in CFA in four
intraperitoneal injections at intervals of 2 wk . 3 d after the last injection, 108 spleen cells
were fused with 5 x 10' X63.Ag8.653 myeloma cells (kindly provided by Dr . H .
Hengartner, Institute of Experimental Pathology, University of Zurich) according to
established methods (13) . Hybrrdomms were selected in Iscove's modified Dulbecco's
medium (KC Biological, Inc .) supplemented with 10% FCS, penicillin (100 U/ml), strep-
tomycin (100 Ag/ml), glutamine (4 mM), sodium pyruvate (1 mM), 2-ME (50 AM),
hypoxanthine (100 AM), aminopterine (0.4 AM), and thymidine (16 AM) .
Screening of Hybridoma Supernatants .
￿
Hybridoma supernatants were first screened for
competitive inhibition of binding of '25I-labeled rhuIFN-y to Raji cells. 2 X 106 Raji cells
per well were incubated with 50 Al of 2 X 10- `° M 121I-labeled rhuIFN-y in culture
medium and 50 A,1 ofeach hybridoma supernatant for 2 hat 4 °C in U-bottomed microtiter
plates . Nonspecific binding was determined by simultaneous addition of 3 X 10-e M
unlabeled rhuIFN-y . Subsequently, the cells were washed three times by centrifugation
in the cold with culture medium and were transferred into counting vials . Binding of
mouse mAbs to cells of the human lymphoma lines Raji, P-3HR,, Daudi, Namalwa, or to
mouse L 1210 cells was determined as follows : 2 X 10 6 cells per well were incubated with
50 dal of hybridoma supernatant for 2 h at 4°C and washed twice as described above .
Subsequently, the cells were incubated with 100 gel per well of a ' 21I-labeled affinity-
purified sheep anti-mouse IgG antibody (Amersham Corp ., Arlington Heights, IL ; 13
ACi/ug ofprotein, -105cpm per well) for 2 h at 4°C and were washed three times before
transfer into counting vials.
Affinity Chromatography. Before conjugation to Affigel-10 (Bio-Rad Laboratories,
Richmond, CA), ascitic fluid from mice carrying the hybridoma A6 (see Results) was
dialyzed against 18% wt/vol Na 2SO. at room temperature, and the precipitate was990 MONOCLONAL ANTIBODIES TO HUMAN y INTERFERON RECEPTORS
dissolved and dialyzed against 0.1 M NaHC08. Conjugation was carried out at a final
protein concentration of 5 mg/ml by mixing 2 ml of wet gel with 2 ml of protein solution.
This suspension was incubated overnight at 4 ° C under continuous gentle agitation.
Subsequently, the gel was washed on a fritted glass funnel with ^-100 ml of each of the
following buffers: TBS/0.1 % Triton X-100; 10 mM Tris/CI (pH 7 .2)/0.5 M KCl/0.5%
Triton X-100 (buffer A); 10 mM Tris/Cl (pH 7.2)/150 mM NaCl/1% Triton X-100/1%
sodiumdeoxycholate/0.1% SDS/10% glycerol (buffer B); 0.2 M glycine/HCl (pH
2 .2)/0.1 % Triton X-100 (elution buffer). After this initial washing procedure the gel was
washed and stored in TBS at 4°C. rhuIFN-y was conjugatedto Affigel-10 under the same
conditions; 2 ml of rhuIFN-y containing 5 mg/ml of protein were dialyzed against 0 .1 M
NaHC08 and mixed with 2 ml of wet gel, and the suspension was incubated overnight at
4 °C under continuous agitation. The subsequent washing steps were the same as for the
conjugation of antibody A6 with one exception; since the biological activity of huIFN-y
is lost at low pH, washing with elution buffer was omitted. For affinity purification a
membrane-enriched fraction from 2 X 10'° Raji cells was lysed by addition of Triton X-
100 to a final concentration of 1 % (wt/vol). After incubation for 10 min on ice, lysates
were clarified at 30,000 g for 15 min at 4° C and the supernatants were adsorbed at 4 ° C
on 400 jl Affigel-10 coupled to antibody A6 at a flow rate of 5 ml/h. Subsequently, the
gel was washed by centrifugation with 10 ml TBS/0.I% Triton X-100, 3 X 10 ml buffer
A and 10 ml of buffer B. The gel was then transferred to a small disposable column (Bio-
Rad Laboratories) and washed with 150 mM NaCI/0.1 % Triton X-100 before application
of 0.8 ml elution buffer. The eluate was immediately neutralized by addition of 200 ul
0 .5 M Tris base and eventually kept frozen at -20°C before further purification. The
same protocol was applied for affinity purification of these eluates on rhuIFN-y coupled
to Affigel-10. Final eluates were dialyzed against 50 mM Tris/Cl (pH 7.2)/0.1 % Triton
X-100 and stored at -20° C. To analyze the protein pattern the eluates were labeled with
251 and subjected to SDS-PAGE. Briefly, 100 ,ul aliquots were reacted for 1 min at room
temperature with 0 .5 mCi carrier-free Na1211 (200 mCi/ml) after addition of 10 A1 0.05%
wt/vol chloramine T. The reaction was stopped by addition of 10 Al 0.05% wt/vol sodium
pyrosulfite and the labeled protein was separated from free iodine by gel filtration on a
prepacked Sephadex G-25 PD-10 column (Pharmacia Fine Chemicals) equilibrated with
50 mM Tris/Cl (pH 7.2)/0.1 % Triton X-100.
SDS-PAGE.
￿
SDS-PAGE was carried out according to Laemmli (14) with 10% polyac-
rylamide gels. Before electrophoresis samples were dialyzed against 50 mM Tris/Cl (pH
6.8)/0.1% Triton X-100 and diluted 3:4 in 0.250 M Tris/Cl (pH 6.8)/1% SDS/40%
glycerol. For SDS-PAGE under reducing conditions samples were heated for 5 min at
96°C after addition of 2% 2-ME (Sigma Chemical Co., St. Louis, MO). Gels were stained
with Bio-Rad Laboratories' silver stain according to the manufacturers protocol.
Protein Transfer to Nitrocellulose.
￿
Electroblotting to nitrocellulose (BA 85; Schleicher
& Schuell, Inc ., Keene, NH) was performed at 80 V/250-350 mA in 25 mM Tris/Cl/10
mM glycine (pH 8.3)/20% methanol for 90 min at 0-5°C. Afterelectroblotting or direct
application of 1-Al samples (dot blot assay), the nitrocellulose was saturated overnight at
room temperature in 10% wt/vol dry skim milk in PBS containing 0.05% wt/vol merthio-
late (Eli Lilly and Co., Indianapolis, IN). To reveal the presence of rhuIFN-y binding
protein nitrocellulose strips were incubated for 2 h at room temperature in 2 X 10-'° M
25I-labeled rhuIFN-y in RPMI 1640 medium containing 10% FCS and 10 mM Hepes
buffer, or in the various hybridoma supernatants. Nonspecific binding was determined in
the presence of 3 X 10-8 M unlabeled rhuIFN-y. Before autoradiography on Fuji RX
film nitrocellulose was washed three times for 10 min at room temperature with the same
medium without IFN and once for 10 min at room temperature in TBS/0.05% (wt/vol)
Tween 20.
Results
Screening and Characterization of mAbs.
￿
'25I-labeled rhuIFN-,y binds to Raji
cells with an apparent dissociation constant of 10-10 M at 4°C as extrapolatedAGUET AND MERLIN
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FIGURE 1.
￿
SDS-PAGE and autoradiography of an "'I-labeled eluate
from a rhuIFN--t column after adsorption of solubilized Raji cell mem-
branes. Analogous eluates were used to immunize a BALB/c mouse for
inducing mAb against huIFN-y receptors .SDS-PAGEwas carried out under
nonreducing conditions as described in Materials and Methods . High mo-
lecular mass standards (Bio-Rad Laboratories) are indicated in kilodaltons .
from linear Scatchard plots . As compared with three other humum lymphoid
cell lines(P-3HR 1 , Daudi, Namalwa; Fig . 3)andalso peripheral human leukocytes
(6), Raji cells express the highest number of specific binding sites for rhuIFN-y
(^-10' sites per cell), while the dissociation constant is virtually the same for all
these cells. Therefore, Raji cells that are easy to grow as large scale cultures were
chosen as starting material for affinity purification of huIFN-y receptors . The
enrichment of membranes by Dounce homogenization and differential centrif-
ugation allows recovery of ^-80% of the cell surface receptors, as revealed by use
of specifically bound '251-labeled rhuIFN-y as a tracer . Affinity purification of
Triton X-100 extracts of enriched Raji cell membranes from ^-5 X 10'° cells on
a rhuIFN-y column yielded -200-400 ttg of eluted protein, as roughly estimated
from silver-stained polyacrylamide gels . This eluate was used for immunization
of one BALB/c mouse . The protein pattern of eluted 1251-labeled protein as
revealed by SDS-PAGE isshown in Fig . 1 . Retrospectively, as compared with the
highly purified proteins after sequential affinity chromatography, the content of
rhuIFN-y binding protein was estimated at <10% of the total protein (Fig . 5A).
mAbs were screened for inhibition of specific binding of 1251-labeled rhuIFN-y
to Raji cells as shown in Fig. 2A . 20 of 1,400 hybridoma supernatant fluids
screened showed such an inhibitory effect . Among these, 13 contained antibodies
that could recognize a cell surface antigen on Raji cells . This binding could be992 MONOCLONAL ANTIBODIES TO HUMAN y INTERFERON RECEPTORS
A3
A3
HYBRIDOMA SUPERNATANTS
FIGURE 2.
￿
(A)Screeningofhybridomasupernatants for inhibition of specific binding of'251-
labeled rhuIFN-y to Raji cellsat areceptor saturating concentration (2 X 10-'° M). (a)Binding
in the absence of antibodies. (b) Nonspecific binding in the presence of excess unlabeled
rhuIFN-y (3 X 10's M). (B) Binding of mAbs to Raji cells as revealed by addition of 1251_
labeled sheepanti-mouse IgGantibodies (SAM). Raji cells were preincubated with hybridoma
supernatants or cell culture medium (0)without (p)or in the presence of3 X 10-sM unlabeled
rhuIFN-y (/). After 2 h the cellswere washed and incubatedwith 1251-labeled SAM.
inhibited competitively by excess unlabeled rhuIFN-y (Fig. 2B), but not by IFN-
a2 (not shown), which interacts with distinct receptors (2). Seven additional
antibodies such as antibody A3 (Fig. 2) failed to bind to Raji cells although they
inhibited specific receptor binding of rhuIFN-y. These antibodies are specific
for rhuIFN-y that was present as a contaminant in the immunogen (since
biological activity and binding capacity of huIFN-y are lost irreversibly at low
pH, washing of the affinity column with elution buffer had been omitted and
therefore noncovalently bound rhuIFN-y was expected to contaminate the
eluates to some extent). As exemplified with antibody A6 and confirmed for the
other putative anti-huIFN-y receptor antibodies, the experiment depicted in
Fig. 3 shows that the number of binding sites revealed by direct binding of 125I-
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CELL LINES
FIGURE 3.
￿
(A) Comparative binding of "'I-labeled rhuIFN-,y to cellsof four human (Raji, P-
3HRI , Daudi, Namalwa) andonemurine (1,1210) lymphoid cell line underthesame conditions
as in Fig. 2A (p). Nonspecific bindingwas determined in thepresence of 3 X 10-s M unlabeled
rhuIFN-,y(/). (B) Comparative binding of mAb A6 to the same cells as revealed by addition
of 121I-labeled SAM(see Fig. 2B).
labeled rhuIFN-y correlates with the amount ofantigen recognized by antibody
A6 on four different human lymphoid cell lines. Mouse 1,1210 cells neither
express rhuIFN-y binding sites nor antigens recognized by antibody A6. All
mAbs selected belong to the IgG class. Preparative quantities ofantibodies were
purified from ascitic fluid from BALB/c mice injected intraperitoneally with the
hybridomas. Ascitic fluid containing anti-receptor antibodies neutralizes the
antiviral activity of rhuIFN-y on WISH cells with titers ranging from 1:640 to
1:2,560 against 8 U/ml of rhuIFN-y. None of the mAbs exhibit an antiviral
effect on WISH cells.
Affinity Purification ofhuIFN-y Receptor Protein.
￿
Antibody A6 was selected for
affinity chromatography since it gave the highest binding signal on Raji cells,
both in hybridoma supernatants (Fig. 2B) and ascitic fluid (not shown). As shown
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FIGURE 4 .
￿
Sequential adsorption and elution of rhuIFN-y binding
proteins from immobilizedmAbs A6 (lanes 1 and 2) or A3 (lanes 3
and 4) and rhuIFN-y, as revealed in a dot blot assay. Nitrocellulose
strips were incubated with 1251-labeled rhuIFN-y without (lanes 1and
3) qr in the presence of excess unlabeled rhuIFN --t (lanes 2 and 4),
andwere washed and incubated for autoradiography . (A) Triton X-
100 extract of a membrane-enriched Raji cell fraction . (B) Same
material after adsorption to the mAb columns . (C) Eluates from the
antibody columns. (D) Eluates from the antibody columns after ad-
sorption to immobilized rhuIFN-y . (E) Eluates from the rhuIFN-y
column .
in Fig . 4, affinity purification of huIFN--y binding proteins from lysates of
enriched Raji cell membranes can be followed in a simple dot blot assay ; an A6
column retains a protein fraction that can bind rhuIFN-y, and this fraction can
be quantitatively adsorbed on a rhuIFN-y column and retains its binding activity
upon elution from this column . As a control, solubilized Raji cell membranes
were adsorbed to immobilized antibody A3 that is specific for huIFN-y (Fig . 2) .
huIFN-y binding proteins could neither be adsorbed noreluted from this column
(Fig . 4) . The protein pattern of 1251-labeled eluates as revealed by SDS-PAGE is
shown in Fig . 5A . Sequential affinity chromatography on antibody A6 and
rhuIFN-y columns yields two major protein species with approximate M, of
90,000 (p90) and 50,000 (p50), respectively . Upon electroblotting to nitrocel-
lulose, both p90 and p50 can bind I25I-labeled rhuIFN-y and this binding can be
displaced by addition of unlabeled rhuIFN-y (Fig . 5B, lanes a and b) but not
IFN-a (not shown) . While the binding to p50 is always reproducible, the capacity
of p90 to bind rhuIFN-y was found to depend on the batch of nitrocellulose
used . As in the final eluate after sequential affinity chromatography on antibody
A6 and rhuIFN-y columns, p90 and p50 are the only rhuIFN binding proteins
revealed upon electroblotting of eluates from an antibody A6 column (Fig . 5B,
lane c), and according to the dot blot assay, (Fig . 4) these proteins are no longer
detectable in such eluates when these have been adsorbed on an rhuIFN-y
column (not shown) . Consistent with its capacity to inhibit the binding of
1251
labeled rhuIFN-y to its cell surface receptors, antibody A6 can also specifically
inhibit the binding of 1251-labeled rhuIFN-y to p90 and p50 (Fig . 5B, lane e) .
SDS-PAGE and electroblotting to nitrocellulose of unadsorbed Raji membrane
lysates reveal a very weak signal corresponding to p50 and no additional rhuIFN-
y binding proteins can be detected (not shown) .
To verify the results obtained with the mAb A6, the same purification
procedure was repeated using antibody B9, which was chosen arbitrarily. It wasAGUET AND MERLIN
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FIGURE 5 .
￿
(A) SDS-PAGE and autoradiography of'25I-labeled sequential eluates from anti-
body A6 andrhuIFN-y columns . Lanes 1-3were run undernonreducing conditions, lanes4-
6 under reducing conditions . High molecular mass standards (Bio-Rad Laboratories) are
indicated in kilodaltons. Lanes 1 and 4 ; eluate from an antibody A6 column (see Fig. 4C) ;
lanes 2 and 5, eluate from an antibody A6 column after adsorption to a rhuIFN-y (see Fig.
4D) ; lanes3 and 6, final eluate from arhuIFN-y column (see Fig. 4E) . (B) Lanes a-b, binding
of "'I-labeled rhuIFN-y to proteins of the final eluate after sequential chromatography of
solubilized Raji cell membranes on antibody A6 and rhuIFN-y columns . The eluate was
subjected to SDS-PAGE under nonreducin conditions and electroblotted to nitrocellulose .
Nitrocellulose strips were incubated with '§'I-rhuIFN-y alone (a) or in presence of excess
unlabeled rhuIFN-y (b) ; lanes c-g, binding of 'z.I-labeled rhuIFN-y to electroblotted proteins
eluted from an antibody A6 before further purification on an rhuIFN-y column . Nitrocellulose
strips were incubated with '"-rhuIFN-y alone (c), in the presence of excess unlabeled rhuIFN-
y (d), in the presence of hybridoma supernatant A6 (e), in the presence of hybridoma
supernatant B9 (f), or in the presence of a hybridoma supernatant containing nonspecific
mAb (g) . The binding proteins were visualized by autoradiography .
ascertained by determining their respective pI that antibodies A6 and B9 are
indeed different .A superimposable pattern of purified proteins with an identical
capacity to bind rhuIFN--y wasobtained when antibody B9 waschosen for affinity
chromatography instead of antibody A6 (not shown) . Antibody B9 can also
inhibit the binding of labeled rhuIFN-'Y to p90 and p50 (Fig . 5B, lanef), though
to a lesser extent than antibody A6 . This difference correlates with the different
capacity of antibodies A6 and B9 to inhibit the binding of I25I-labeled rhuIFN--y
to cell surface receptors (Fig. 2A) . It was confirmed by use of a 1251-labeled sheep
anti-mouse IgG antibody that both antibodies A6 and B9 can bind to the same
proteins as '25I-labeled rhuIFN-^y (not shown) .
Sequential affinity chromatography of a lysate of 80 ml containing about 10
mg/ml of protein and corresponding to about 2 x 10'° Raji cells yields 1 ml of
a final eluate with about 500 ng of p50, as estimated on silver-stained polyacryl-996 MONOCLONAL ANTIBODIES TO HUMAN y INTERFERON RECEPTORS
amide gels. The proportion of p90 varies from one preparation to another but
never exceeds 30% ofp50 (Fig. 5A). The yield and the quantitative enrichment
of rhuIFN-y binding proteins after the various purification steps are difficult to
evaluate. Based on an estimation of 104 receptor molecules per Raji cell, a
membrane enriched fraction of 2 X 10'° cells would contain about 17 ,Ag ofp50.
Accordingly, the final recovery of 500 ng p50 would amount to ^-3% . As
suggested by the different intensities of dots (Fig. 4) and also protein bands in
autoradiography, rhuIFN-y binding proteins are markedly enriched upon puri-
fication on theantireceptor antibody column. Dilution series in the dot blot assay
indicate that the enrichment after affinity chromatography on the antibody
column is ^"10-20-fold (not shown). Clearly, rhuIFN-y binding proteins eluted
from the antireceptor antibody column are recovered to >50% upon adsorption
and elution from a rhuIFN-y column (Fig. 4). Thus, when estimated in the dot
blot assay, the recovery ofrhuIFN-y binding proteins after sequential chroma-
tography on both columns would amount to ^-10%.
Assuming that the estimation of 500 ng/ml of protein p50 in the final eluate
is correct, this eluate should be able to neutralize the antiviral activity of-3,000
U/ml of huIFN-y, provided that the binding affinity of the soluble receptor is
the same as for the native cell surface molecule. We were not able, however, to
detect any IFN-y neutralizing activity of the huIFN-y binding proteins eluted
from the affinity columns. The reasons for this are not known at present. It is
possible that the dilution in the IFN neutralization assay of Triton X-100
containing eluates to detergent concentrations that are not cytotoxic accounts
for a destabilization or a loss ofaffinity ofsoluble receptor proteins.
Discussion
We have produced monoclonal anti-huIFN-y receptor antibodies as a tool for
purification ofreceptor protein to analyze its structure and gene(s). A Triton X-
100 extract ofa membrane-enriched Raji cell fraction was affinity purified on a
rhuIFN-y column and the eluate served as immunogen (Fig. 1). Raji cells were
chosen for their comparatively high level of expression of specific huIFN-y
binding sites (Fig. 3). Since binding of labeled rhuIFN-y was the only available
receptor assay, mAbs were selected for inhibition of ligand binding to the
receptor. Among such inhibitory antibodies some were found to bind rhuIFN-y
that was contaminating the immunogen (see Results). The others are character-
ized by the following properties: they bind to the surface of cells that express
huIFN-y receptors, but not to heterologous cells (Figs. 2 and 3). This binding is
proportional to the number of IFN-y binding sites expressed on different cells
(Fig. 3) and can be inhibited competitively by addition of rhuIFN-y (Fig. 2).
Altogether these findings suggest that this second group of antibodies is inter-
acting specifically with epitopes of IFN-'Y receptors. Concordant with the partial
inhibition ofligand binding, ascitic fluid from hybridoma-carrying mice has some
neutralizingeffect on the antiviral activity ofrhuIFN-yon WISH cells, suggesting
that similar epitopes are recognized on these cells. Antibodies to receptors may
mimic the action of peptide ligands such as epidermal growth factor (15, 16).
Yet, none of the anti-huIFN-y receptor antibodies exhibit antiviral activity on
WISH cells. Affinity purification ofrhuIFN-y binding proteins from solubilizedAGUET AND MERLIN
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Raji cell membranes can be easily followed in a dot blot assay (Fig. 4). Thus, a
column containing the mAb A6 retains a protein fraction that, upon elution, is
still able to specifically bind '2'I-labeled rhuIFN-y. This fraction can be read-
sorbed and eluted from a rhuIFN-y column. As compared with the weak specific
signal in the starting material, both eluates from antibody A6 and rhuIFN-y
columns contain markedly concentrated rhuIFN-y binding proteins. SDS-PAGE
of the final eluate reveals an enrichment oftwo main heterogeneous, probably
glycosylated, protein species, p90 andp50 (Fig. 5A). A comparison ofthe labeled
eluate from a rhuIFN-y column (Fig. 1) with the eluate obtained by sequential
affinity chromatography on antireceptor antibody and rhuIFN-y columns (Fig.
5A) illustrates the contribution ofimmobilized antireceptor mAbs for additional
purification ofreceptor proteins. A superimposable pattern ofpurified rhuIFN-
y binding proteins was reproduced when a different antireceptor antibody
(antibody B9) was chosen for affinity chromatography instead ofantibody A6. It
is also noteworthy that similar results were obtained when the purification
sequence was inverted with an rhuIFN-y column preceding the antibody A6
column (data not shown).
Upon electroblotting to nitrocellulose, both proteins p90 and p50 can bind
'25I-labeled rhuIFN-y (Fig. 5B). This bindingis specifically displaceable by excess
unlabeled rhuIFN-y and also by the anti-huIFN-y receptor mAbs, but not by
control antibodies. Hence, it seems likely that p90 and p50 represent at least a
part of huIFN-y receptors. The electrophoretic migration of both p90 and p50
was virtually the same under nonreducing and reducing conditions (Fig. 5A),
and therefore, a simple monomer-dimer relationship between both proteins
seems unlikely. The marked heterogeneity of p50 suggests that this protein is
glycosylated. An additional, more homogeneous rhuIFN-y binding protein spe-
cies seems to be hidden within the diffuse band ofp50 (Fig. 5), and preliminary
results obtained with two-dimensional electrophoresis confirm this observation.
In view of its rather low molecular weight, p50 could be a degradation product;
alternatively, it might represent a subunit of the huIFN-y receptor. At present,
however, the relationship between p90 and p50 is unclear.
Several reports (9-11) on the analysis ofcrosslinked ligand-receptor complexes
suggest an M,. range for huIFN-y receptors between 100,000 and 150,000.
Recently, analogous crosslinkingexperiments (12) with various cell lines revealed
a marked heterogeneity ofligand-receptor complexes with three main M, species
of 70,000, 92,000, and 160,000, respectively. It remains to be established
whether these different species represent subunitsor split products ofthe huIFN-
y receptor. The similarity ofp90 and the proteins that make up the diffuse p50
band with regard to binding of both rhuIFN-y and also the mAbs used for their
purification suggests an extensive homology around the respective binding sites.
Purified p90 and p50 separated by preparative SDS-PAGE and used as immu-
nogens should give rise to mAbs with antireceptor properties similar to those
described here, and this would underpin the role of these proteins as a part of
the huIFN-y receptor. In addition, the characterization of a broader spectrum
ofepitopes could help to further elucidate the relationship between these various
protein species.998 MONOCLONAL ANTIBODIES TO HUMAN y INTERFERON RECEPTORS
Summary
mAbs against human IFN--y (huIFN-y) receptors were obtained by immunizing
a BALB/c mouse with eluatesfrom immobilized recombinant huIFN-y (rhuIFN-
y) on which lysates of enriched Raji cell membranes had been adsorbed . mAbs
were selected for competitive inhibition of receptor binding of "5I-labeled
rhuIFN-y. The following additional properties suggest that these antibodies are
specific forhuIFN-y receptors: they bind to the surface ofhuman cells expressing
IFN-y receptors but not to heterologous cells; this binding is inhibited competi-
tively by addition of rhuIFN-y; the number of binding sites revealed by direct
binding of '21I-labeled rhuIFN-y correlates with the amount of antigen recog-
nized by themAbs on different cell lines. ATriton X-100extract ofa membrane-
enriched fraction ofhuman Raji cells was affinity purified with these mAbs and
the eluates from such columns were further purified on immobilized rhuIFN-y.
As revealed by SDS-PAGE, the final eluate contained two major protein bands
with approximate Mr of 90,000 (p90) and 50,000 (p50), respectively. Both
proteins were able to specifically bind
121I-labeled rhuIFN-y upon electroblotting
to nitrocellulose. This binding could be inhibited by thehuIFN-y receptor mAbs,
suggesting that the same epitopes are recognized on p90, p50, and on the cell
surface. Therefore, these proteins most likely represent at least apart of huIFN-
y receptors.
We gratefully acknowledge the expert technical assistance of Marianne Hassig and
Florence Beranger.
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